

Public Assessment Report

Scientific discussion

Macrogol and electrolytes Sandoz 13.8 g powder for oral solution

NL/H/4382/001/MR

Date: 7 May 2018

I INTRODUCTION

Based on the review of the data on quality, safety and efficacy, it is considered that Macrogol and electrolytes Sandoz 13.8 mg powder for oral solution could be approved.

Macrogol and electrolytes Sandoz is indicated for the treatment of chronic constipation.

The application is submitted as abridged application according to Article 10(1) of Directive 2001/83/EC, claiming to be a generic medicinal product of Movicol 13.8 g sachet Powder for Oral Solution, first authorised in the UK to Norgine Limited in December 1995.

No new non-clinical studies were conducted, which is acceptable given that the products contain a widely-used, well-known active substance. No clinical studies have been performed and none are required for these applications as the pharmacology of macrogol 3350, sodium chloride, sodium hydrogen carbonate, potassium chloride is well-established.

For manufacturing sites within the Community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites.

The RMS considers that the pharmacovigilance system as described by the MAH fulfils the requirements and provides adequate evidence that the MAH has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.

The MAH has provided adequate justification for not submitting a Risk Management Plan.


Following a Change of Ownership procedure, the Marketing Authorisation Hermalax Powder for oral solution, sachet was granted to Sandoz Limited on 10 November 2011 (UK/H/4219/001/DC).

The product name of Hermalax Powder for oral solution, sachet was changed to Compound Macrogol 13.8 g Powder for Oral Solution on 14 June 2012, and subsequently to Macrogol and electrolytes Sandoz 13.8 g powder for oral solution during the RMS change on 3 May 2018.

II. QUALITY ASPECTS

- II.1 Introduction
- II.2 Drug substances

Macrogol 3350 INN/Ph.Eur name: Macrogol 3350 Structural formula:



Molecular formula: H-(OCH₂-CH₂)_n-OH

Appearance:White or almost with solid with a waxy or paraffin-like appearance.Solubility:Very soluble in water and in methylene chloride, very slightly soluble
in alcohol, practically insoluble in fatty oils and in mineral oils.

Sodium Hydrogen Carbonate

INN: Sodium hydrogen carbonate Structure:

Physical form: Solubility:	A white powder (crystalline) Sparingly soluble in water
Molecular formula: Molecular weight:	NaHCO₃ 84.01
Sodium chloride INN/Ph.Eur name: Molecular formula:	Sodium chloride NaCl
Appearance: Solubility:	White, crystalline powder or colourless crystals or white pearls Freely soluble in water, practically insoluble in ethanol.
Molecular weight:	58.4
Potassium chloride INN/Ph.Eur name: Molecular formula:	Potassium chloride KCl
Appearance: Solubility:	White or almost white crystalline powder or colourless crystals. Freely soluble in water, and practically insoluble in anhydrous ethanol.
Molecular weight:	74.6

Macrogol 3350, sodium hydrogen carbonate, sodium chloride and potassium chloride comply with their relevant European Pharmacopoeia monographs.

All aspects of the manufacture of the active substances macrogol 3350, sodium chloride, sodium hydrogen carbonate and potassium chloride from its starting materials are controlled by Certificates of Suitability.

An appropriate retest period has been proposed based on stability data submitted for the active substances.

Appropriate specifications are provided for the active substances, with suitable test methods and limits. The methods of testing and limits for residual solvents are in compliance with current guidelines. Batch analysis data are provided and comply with the proposed specifications.

Appropriate proof-of-structure data have been supplied for the active pharmaceutical ingredients. All potential known impurities have been identified and characterised. Suitable Certificates of Analysis have been provided for all reference standards used.

Appropriate stability data have been generated showing the active substances to be physically and chemically stable drugs, and supporting appropriate retest periods.

II.3 Medicinal Product

Other Ingredients

Other ingredients are pharmaceutical excipients colloidal anhydrous silica, saccharin sodium, orange flavour (containing flavouring substances and flavouring preparations, maltodextrin, acacia gum and alpha-tocopherol) and lemon lime flavour (consisting of flavouring preparations, maltodextrin, mannitol, gluconolactone, sorbitol (E420), acacia gum, colloidal anhydrous silica).

None of the excipients used contain material of animal or human origin.

No genetically modified organisms (GMO) have been used in the preparation of these products.

Pharmaceutical Development

The objective of the development programme was to produce products that could be considered generic medicinal products of Movicol 13.8 g sachet Powder for Oral Solution.

The applicant has provided suitable product development sections. Justifications for the use and amounts of each excipient have been provided and are valid.

Manufacturing Process

Satisfactory batch formulae have been provided for the manufacture of the products, along with an appropriate account of the manufacturing process. The manufacturing process has been validated and has shown satisfactory results. Process validation data on commercial-scale batches of each strength have been provided.

Finished Product Specification

The finished product specifications proposed for the products are acceptable. Test methods have been described and have been adequately validated, as appropriate. Batch data have

been provided that comply with the release specifications. Certificates of Analysis have been provided for any working standards used.

Container-Closure System

These products are packaged in sachets composed of paper, ethylene/methacrylic acid copolymer and aluminium then packed in a carton box.

Pack sizes are 2, 6, 8, 10, 20, 30, 50, 60 (2x30) and 100 (2x50) sachets.

Satisfactory specifications and Certificates of Analysis have been provided for all packaging components. All primary product packaging complies with EU legislation regarding contact with food.

Stability of the product

Stability studies were performed on batches of the finished products in the packaging proposed for marketing and in accordance with current guidelines. These data support a shelf-life of 36 months with storage instructions, 'Do not store above 25°C'.

For the reconstituted solution the shelf-life is 24 hours with storage conditions 'Store covered in a refrigerator (2°C to 8°C)'.

II.4 Discussion on chemical, pharmaceutical and biological aspects

There are no objections to the approval of this application from a pharmaceutical viewpoint.

No user testing results have been submitted for the PL for this product. A satisfactory bridging report was submitted with a similar PL for an already approved product, containing Macrogol 3350, sodium chloride, sodium hydrogen carbonate and potassium chloride. The PL is satisfactory.

III. NON-CLINICAL ASPECTS

The pharmacodynamics, pharmacokinetics and toxicological properties of macrogol 3350, sodium chloride, sodium hydrogen carbonate and potassium chloride are well-known. As these are widely used, well-known active substances, the applicant has not provided any additional studies and none are required.

The non-clinical expert report has been written by an appropriately qualified person and is a suitable summary of the non-clinical aspects of the dossier.

The Marketing Authorisation Holder has provided adequate justification for not submitting an Environmental Risk Assessment

IV. CLINICAL ASPECTS

IV.1 Introduction

This assessment report represents an evaluation of the key elements of the information provided by the company in the dossier.

IV.2 Pharmacokinetics and IV.3 Pharmacodynamics

No new pharmacokinetic or pharmacodynamic data were submitted with this application and none were required, as per the Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98, if the test product is an aqueous oral solution at the time of administration and contains an active substance in the same concentration as an approved oral solution, bioequivalence studies may be waived, if the excipients contained in it do not affect gastrointestinal transit, absorption, solubility or invivo stability of the active substance.

IV.4 Clinical efficacy

No new efficacy data were submitted with this application and none were required.

IV.5 Clinical safety

No new safety data were submitted with this application and none were required.

IV.7 Discussion on the clinical aspects

SUMMARY OF PRODUCT CHARACTERISTICS (SPC), PATIENT INFORMATION LEAFLET (PIL) AND LABELLING

The SmPCs, PLs and labelling are medically satisfactory and consistent with those for the reference product, where appropriate.

CLINICAL EXPERT REPORT

The clinical expert report has been written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier.

MAA FORM

The MAA Forms are medically satisfactory.

CONCLUSIONS

It is recommended that Marketing Authorisations are granted for these applications.

V. USER CONSULTATION

No user testing results have been submitted for the PL for this product. A satisfactory bridging report was submitted with a similar PL for an already approved product, containing Macrogol 3350, sodium chloride, sodium hydrogen carbonate and potassium chloride. The PL is satisfactory.

IV. OVERALL CONCLUSION, BENEFIT/ RISK ASSESSMENT AND RECOMMENDATION

QUALITY

The important quality characteristics of Macrogol are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance.

NON-CLINICAL

No new non-clinical data were submitted and none are required for an application of this type.

EFFICACY

No bioequivalence studies have been performed and none are required for these applications, given the composition of the products and its intended route of administration.

No new or unexpected safety concerns arise from these applications.

The SmPCs, PLs and labelling are satisfactory and consistent with that for the reference product.

BENEFIT/RISK ASSESSMENT

The quality of the product is acceptable and no new non-clinical or clinical safety concerns have been identified. Extensive clinical experience with macrogol 3350, sodium chloride, sodium hydrogen carbonate and potassium chloride is considered to have demonstrated the therapeutic value of the compounds. The risk benefit is, therefore, considered to be positive.

STEPS TAKEN AFTER INITIAL PROCEDURE – SUMMARY

Scope	Procedure number	Product Information	Date of start of the	Date of end of procedure	Approval/ non	Assessment report
		affected	procedure	- procedure	approval	attached
Updated certificate from an already approved	UK/H/4219/ 001/IB/025		01/12/2017	02/01/2018	Approved	No
manufacturer.						
Updated certificate from an already approved manufacturer.	UK/H/4219/ 001/IB/024		01/12/2017	31/12/2017	Approved	No
Updated certificate from an already approved manufacturer.	UK/H/4219/I B/026/G		22/11/2017	07/12/2017	Approved	No
Change of the address in Spain of the MAH	UK/H/4219/ 001/IA/023/ G		16/03/2017	14/04/2017	Approved	No
Implementation of change(s) for which no new additional data is required to be submitted by the MAH.	UK/H/4219/ 001/IB/022		21/02/2016	28/06/2016	Approved	No
Change outside the approved specifications limits range for the active substance.	UK/H/4219/ 001/II/021		24/07/2015	19/02/2016	Approved	Yes
Change in the name of a manufacturer	UK/H/4219/ 001/IA/020/ G		10/01/2015	23/02/2015	Approved	No
Renewal procedure	UK/H/4219/ 001/R/001		06/11/2017	06/12/2017	Approved	Yes
To register the replacement of Ph. Eur. 2.9.40 (Potassium, Sodium, Hydrogen Carbonate, Macrogol 3350) with Ph. Eur. 2.9.6 (Potassium,	UK/H/4219/ 001/IA/019		30/10/2014	26/11/2014	Approved	No

	1				1	,
Hydrogen						
carbonate) and						
to Ph. Eur.						
2.9.5., for the						
finished						
product.						
To update of	UK/H/4219/	SmPC, PL	17/10/2014	21/04/2015	Approved	Yes
the SmPC and	001/11/018					
consequentially						
the leaflet as						
the result of a						
repeat use						
procedure						
UK/H/4219/001						
/E01 (EOP, Day						
90:						
03/06/2013) as						
a fulfilment of						
the						
commitment						
made by the						
MAH within						
Responses to						
Day 60						
comments from						
CMSs: NL, ES						
and IE and also						
in line with the						
QRD template						
Change in the	UK/H/4219/I		28/08/2014	27/09/2014	Approved	No
address of the	A/017/G					
MAH						
1) To register	UK/H/4219/I		21/08/2014	11/09/2014	Approved	No
replacement of	A/016/G					
Excipient						
Flavour Lemon-						
Lime						
2) To register						
replacement of						
Flavour Orange						
Evogran.						
3) To register						
minor changes						
to the						
manufacturing						
process.						
1) To register	UK/H/4219/I		17/05/2014	26/06/2014	Approved	No
replacement of	A/014/G					
Excipient						
Flavour Lemon-						
Lime						
2) To register						
replacement of						

	1	[T	I	1
Flavour Orange					
Evogran.					
To register					
minor changes					
to the					
manufacturing					
process.					
To delete tests	UK/H/4219/	28/05/2014	29/09/2014	Approved	No
from	001/IB/015				
specification of					
lemon lime and					
orange flavour					
and to delete					
non-significant					
specification					
parameters.					
To submit the	UK/H/4219/	09/04/2013	29/08/2013	Approved	Yes
risk	001/11/013	20, 0 , 2010			
management	50 <u>-</u> ,, 0 <u>1</u> 0				
plan, (RMP).					
To add a	UK/H/4219/	06/11/2013	27/11/2013	Approved	No
secondary	001/IA/012	00/11/2013	27/11/2013	Approved	NO
packaging site,	001/1A/012				
to the licence.		05/02/2012	02/06/2012	Australia	Na
Repeat use	UK/H/4219/	05/03/2013	03/06/2013	Approved	No
procedure to	001/E/001				
register the					
product in					
Spain, Italy,					
Ireland and					
Portugal.					
To register the	UK/H/4219/	31/10/2012	26/11/2012	Approved	No
introduction of	001/IA/011				
the					
Pharmacovigila					
nce System					
Master File					
(PSMF) of					
Sandoz					
according to					
the CMDh					
recommendatio					
n for					
classification					
variations					
according to					
Art. 5 of					
commission					
Regulation (EC)					
No 1.23412008.					
To change the	UK/H/4219/	08/11/2012	09/01/2013	Approved	No
name of the	001/IB/010				
medicinal					
	1	1	1	1	1

	I	T	I	T	I	
product in						
Luxembourg						
from 'Macrolax						
poudre pour						
solution						
buvable' to						
'Macrogol +						
elektrolytes						
Sandoz poudre						
pour solution						
buvable' due to						
marketing						
reasons.						
To update the	UK/H/4219/		09/07/2012	06/09/2012	Approved	No
frequency of	001/IB/009					
testing for						
uniformity of						
dosage units						
(Content						
uniformity) to						
Skip testing:						
every 10th						
batch.			00/07/2012	20/07/2012		
To extend the	UK/H/4219/I		09/07/2012	30/07/2012	Approved	No
shelf life of the	B/008/G					
finished						
product to 36						
months and to						
extend the shelf						
life of the						
reconstituted						
solution to 24						
hours.						
To add a	UK/H/4219/I	PL	21/06/2012	17/08/2012	Approved	No
finished	B/005/G		, ,			
product	_,, .					
manufacturer,						
primary and						
secondary						
packager, batch						
release site and						
QC site, To also						
add a 'leak test'						
as an						
alternative the						
in-process test						
procedure to						
the 'Tightness						
of seals' test.						
B.II.b).2.b). 1	UK/H/4219/I		21/05/2012	21/06/2012	Approved	No
Not including	A/006/G		,,	,		-
batch	,,.					
control/testing						
controlytesting						

		I	I	I	I	,
B.II.d).2. a) Minor changes to an approved test procedure B.III.1.a). 2 Updated certificate from an already approved manufacturer B.III.1.a). 3 New certificate from a new manufacturer						
(replacement or						
addition)						
To change the name of the medicinal product from "Laxmac, poeder voor orale oplossing" to "Macrogol + elektrolytes Sandoz poeder voor drank" in Belgium only.	UK/H/4219/ 001/IB/003	SmPC, PL and labelling	11/05/2012	07-06-2012	Approved	No
PL 17740/0008- 0018	N/A	Licence cancellation	N/A	Licence was cancelled on 17/12/2014	Approved	No
Change of ownership procedure for PL 17740/0009 to PL 04416/1319 (Sandoz Limited)	N/A	Change of ownership	N/A	Change of ownership procedure from Hermes Arzneimittel GmbH to Sandoz Limited on 10/11/2011	Approved	No
For PL 04416/1319- 0002; To change the name of the product in the UK from Hermalax, powder for oral solution to Compound Macrogol	UK/H/4219/ 001/IB/003	SmPC, PIL and labelling	29/02/2012	30/03/2012	Approved on 14/06/201 2	No

13.8g Powder						
for Oral						
Solution						
For PL		SmPC and	17/10/2014	09/04/2015	Approved	Yes-see
-	UK/H/4219/	PIL.	17/10/2014	08/04/2015	Approved	
04416/1319- 0022: To	001/11/018	PIL.			0n 21/04/201	annex 1
					21/04/201	
update sections					5	
4.1, 4.2, 4.4,						
4.5, 4.6, 4.8 and 5.3 of the SmPC						
and						
consequentially						
the leaflet as						
the result of a						
repeat use						
procedure						
UK/H/4219/001						
/E01 (End of						
procedure, Day						
90:						
03/06/2013) as						
a fulfilment of						
the						
commitment						
made by the						
applicant also in						
line with the						
QRD template.						

ANNEX 1

Product:	Compound Macrogol 13.8g Powder for Oral Solution
Marketing Authorisation Holder: Active Ingredient(s):	Sandoz Limited macrogol 3350, sodium chloride, sodium hydrogen carbonate and potassium chloride
Type of Procedure:	Mutual Recognition
Submission Type:	Variation
Submission Category:	Type II
Submission Complexity:	Standard
EU Procedure Number (if applicable):	UK/H/4219/001/II/018
Dessent	

Reason:

To update sections 4.1 (Therapeutic indications), 4.2 (Posology and method of administration), 4.4 (Special warnings and precautions for use), 4.5 (Interaction with other medicinal products and other forms of interaction), 4.6 (Fertility, pregnancy and lactation), 4.8 (Undesirable effects), 5.1 (Pharmacodynamic properties) and 5.3 (Preclinical safety data) of the SmPC and consequentially the leaflet to fulfil a regulatory commitment agreed during the mutual recognition procedure NL/H/4382/001/E01 (concluded on 03/06/2013). The product information (SmPC and PIL) has also been revised in line with the QRD template.

Supporting Evidence

Revised SmPC fragments and PL.

Evaluation

The proposed changes to the SmPC and PL are acceptable. The updated SmPC fragments and PIL have been incorporated into the Marketing Authorisation.

Conclusion

Approved on 28 April 2015.